Shanghai, China, April 17, 2016: Tractus’ Corporate Finance Consultant Giselle Zhao represented SynAgile Corporation at the DemoHealth 2016 Innovative Healthcare Business Competition, an event that coincided with the 75th China International Medical Equipment Fair held at Shanghai’s National Exhibition and Convention Center.
From a large pool of applicants, DemoHealth selected 12 companies for the final healthcare business competition and awarded second prize to SynAgile’s proprietary intraoral continuous drug delivery platform, OraFuse™ and DopaFuse™.
SynAgile’s first product, DopaFuse™, is designed to help patients suffering the debilitating effects of Parkinson’s Disease by delivering a continuous dose of levodopa and carbidopa (a drug combination which is prescribed to virtually all Parkinson’s patients) into the mouth at a constant and controlled rate, thereby dramatically reducing motor fluctuations. The therapy targets a huge global market. With the number of persons suffering from Parkinson’s exceeding 6.3 million, the addressable market opportunity for this application alone is estimated at more than US$2 billion. The company recently completed its Phase 2a clinical study where all primary and secondary endpoints were met.
SynAgile was founded by highly successful serial inventor-entrepreneurs Ephraim Heller (CEO) and Adam Heller (CSO). The father-son team have over 300 patents (most in use) and an enviable track record which includes the founding of AngioScore and TheraSense (which went public and was later sold to Abbott Labs for $1.2 billion). Adam Heller is an awardee of the US National Medal of Technology and Innovation, the highest honor the United States can confer to a US citizen for achievements related to technological progress
Demohealth invited 10 managing directors from investment firms and medical device associations to form the judging panel including Dr. Guan Yan, the Secretary General of China Medical Device Industry Association, Smart and Mobile Health branch, Mr. Xu Zewei, Deputy Secretary General of Shenzhen Medical Device Industry Association, Mr. Ai Changjun, General Manager of the Listing Management Department, Shanghai Equity Exchange, Sally Liu, Founding Partner of Angel China, Bruce Xiao, Partner of Essentials Capital, Mr. Wanglei, CEO of Shanghai Houlu Investment, and Dr. Nilin, Managing Director of Frontline Bioventures. The event was co-sponsored and launched by Sino-US United Technologies (Beijing) Co,.Ltd, DemoHealth Innovative Healthcare, Utou Space, co-hosted by China Medical City, and supported by dozens of news agencies and organizations.
SynAgile is a biopharmaceutical company focused on developing and commercializing transformative therapeutics using its proprietary OraFuse™ intraoral continuous dosing technology, with an initial focus on treating debilitating motor complications in patients with Parkinson’s disease using its DopaFuse™ levodopa-carbidopa therapy.
About Tractus Asia Limited
Tractus Asia Ltd. is a leading Asia-based foreign direct investment advisory firm focused on assisting government agencies, multilaterals and companies with their Asia trade, investment and growth strategies. We work to develop the most cost-effective approaches for our clients to establish operations, make acquisitions, expand, or diversify their manufacturing and service industry investments throughout Asia.